Table 1.
Characteristics of patients treated with NACT, ACT or no CHT
| Characteristic | No chemotherapy, N = 56,7531 | NACT, N = 10,3721 | ACT, N = 27,1071 | NACT + ACT,N = 4061 |
|---|---|---|---|---|
| Age | 66 (5676) | 52 (4461) | 58 (4966) | 50 (4260) |
| Sex | ||||
| Female | 56,368 (60%) | 10,346 (11%) | 26,920 (29%) | 406 (0.4%) |
| Male | 385 (64%) | 26 (4.3%) | 187 (31%) | 0 (0%) |
| Year of diagnosis | ||||
| 2007 | 2285 (55%) | 202 (4.9%) | 1631 (40%) | 6 (0.1%) |
| 2008 | 3260 (55%) | 339 (5.8%) | 2286 (39%) | 9 (0.2%) |
| 2009 | 3923 (57%) | 380 (5.5%) | 2621 (38%) | 11 (0.2%) |
| 2010 | 4100 (57%) | 410 (5.7%) | 2660 (37%) | 6 (< 0.1%) |
| 2011 | 4268 (58%) | 522 (7.1%) | 2559 (35%) | 19 (0.3%) |
| 2012 | 5155 (60%) | 691 (8.0%) | 2718 (32%) | 26 (0.3%) |
| 2013 | 5301 (62%) | 750 (8.7%) | 2523 (29%) | 40 (0.5%) |
| 2014 | 5419 (61%) | 960 (11%) | 2361 (27%) | 75 (0.9%) |
| 2015 | 5499 (62%) | 1204 (13%) | 2172 (24%) | 49 (0.5%) |
| 2016 | 5853 (62%) | 1593 (17%) | 1956 (21%) | 38 (0.4%) |
| 2017 | 5683 (61%) | 1716 (18%) | 1918 (20%) | 50 (0.5%) |
| 2018 | 6007 (64%) | 1605 (17%) | 1702 (18%) | 77 (0.8%) |
| Tumor size | ||||
| T0 | 117 (66%) | 11 (6.2%) | 47 (27%) | 1 (0.6%) |
| TIS | 634 (74%) | 10 (1.2%) | 208 (24%) | 0 (0%) |
| T1 | 27,520 (68%) | 2766 (6.8%) | 10,113 (25%) | 93 (0.2%) |
| T2 | 12,313 (46%) | 5377 (20%) | 8780 (33%) | 217 (0.8%) |
| T3 | 1339 (41%) | 856 (26%) | 1010 (31%) | 39 (1.2%) |
| T4 | 1441 (52%) | 825 (30%) | 487 (17%) | 37 (1.3%) |
| Missing | 13,389 (66%) | 527 (2.6%) | 6462 (32%) | 19 (< 0.1%) |
| Nodal stage | ||||
| N0 | 47,121 (69%) | 5330 (7.8%) | 15,916 (23%) | 200 (0.3%) |
| N1 | 7144 (37%) | 4262 (22%) | 7957 (41%) | 161 (0.8%) |
| N2 | 1165 (31%) | 549 (15%) | 2032 (54%) | 18 (0.5%) |
| N3 | 632 (33%) | 169 (8.9%) | 1100 (58%) | 7 (0.4%) |
| Missing | 691 (79%) | 62 (7.1%) | 102 (12%) | 20 (2.3%) |
| Grading | ||||
| G1 | 11,541 (90%) | 68 (0.5%) | 1151 (9.0%) | 5 (< 0.1%) |
| G2 | 36,539 (69%) | 1819 (3.4%) | 14,649 (28%) | 111 (0.2%) |
| G3 | 7367 (35%) | 2619 (12%) | 10,839 (51%) | 276 (1.3%) |
| G4 | 28 (65%) | 4 (9.3%) | 11 (26%) | 0 (0%) |
| Missing | 1278 (17%) | 5862 (77%) | 457 (6.0%) | 14 (0.2%) |
| Type of surgery | ||||
| BCS | 42,273 (62%) | 6948 (10%) | 18,981 (28%) | 233 (0.3%) |
| MAS | 11,759 (57%) | 2984 (14%) | 5755 (28%) | 150 (0.7%) |
| BCS-MAS | 2721 (49%) | 440 (7.9%) | 2371 (43%) | 23 (0.4%) |
| Subtype | ||||
| HR + /HER2− | 48,578 (70%) | 3962 (5.7%) | 16,883 (24%) | 99 (0.1%) |
| HR−/HER2− | 2497 (26%) | 2915 (30%) | 4136 (43%) | 183 (1.9%) |
| HR + /HER2 + | 2360 (28%) | 2116 (26%) | 3728 (45%) | 77 (0.9%) |
| HR−/HER2 + | 937 (24%) | 1216 (31%) | 1737 (44%) | 37 (0.9%) |
| Missing | 2381 (75%) | 163 (5.1%) | 623 (20%) | 10 (0.3%) |
ACT adjuvant chemotherapy, NACT neoadjuvant chemotherapy, NACT + ACT neoadjuvant chemotherapy plus adjuvant chemotherapy, BCS breast-conserving surgery, MAS mastectomy, BCS-MAS breast-conserving surgery followed by mastectomy